Fitness or fatness: The debate continues for AMP-activated protein kinase in heart function

Current Cardiology Reviews

Volumn 2, Issue 2, 2006, Pages 117-123

  Shen, Qingwu ^a   Du, Min ^a   Ren, Jun ^a  

^a UNIVERSITY OF WYOMING   (United States)

Author keywords

AMP activated protein kinase; Cardiac; Contraction; Hypertrophy

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; ADIPOCYTOKINE; ADIPONECTIN; CYCLOOXYGENASE 2; ELONGATION FACTOR 2; FATTY ACID; GLUCOSE; GLYCOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LEPTIN; MITOGEN ACTIVATED PROTEIN KINASE P38; TUBERIN; TUMOR NECROSIS FACTOR ALPHA;

BRAIN VENTRICLE DILATATION; CARDIOVASCULAR DISEASE; CELL ENERGY; CELL GROWTH; DIABETES MELLITUS; DRUG TARGETING; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME ACTIVITY; FATTY ACID OXIDATION; FITNESS; FOOD INTAKE; GENE MUTATION; GENE TARGETING; GLUCOSE METABOLISM; GLYCOGEN METABOLISM; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE FUNCTION; HEART VENTRICLE HYPERTROPHY; HEAT SHOCK; HOMEOSTASIS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; HYPOXIA; INSULIN RESISTANCE; ISCHEMIA; METABOLIC DISORDER; OBESITY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REENTRY ARRHYTHMIA; REVIEW; STRESS; WOLFF PARKINSON WHITE SYNDROME;

EID: 33746133584     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340306777013574     Document Type: Review

References (62)

1. Hardie DG. AMP-activated protein kinase: the guardian of cardiac energy status. J Clin Invest 2004; 114(4):465-468.
2. Hawley SA, Davison M, Woods A, Davies SP, Beri RK, Carling D et al. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol Chem 1996; 271(44):27879-27887.
3. Hardie DG, Carling D. The AMP-activated protein kinase-fuel gauge of the mammalian cell? Eur J Biochem 1997; 246(2):259-273.
4. Ingwall JS. Is creatine kinase a target for ANT-activated protein kinase in the heart? J Mol Cell Cardiol 2002; 34(9):1111-1120.
5. Hardie DG. New roles for the LKB1->AMPK pathway. Curr Opin Cell Biol 2005; 17(2):167-173.
6. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003; 2(4):28.
7. Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 2004; 428(6982):569-574.
8. Shen QW, Jones CS, Kalchayanand N, Zhu MJ, Du M. Effect of dietary alpha-lipoic acid on growth, body composition, muscle pH, and AMP-activated protein kinase phosphorylation in mice. J Anim Sci 2005; 83(11):2611-2617.
9. Baron SJ, Li J, Russell RR, III, Neumann D, Miller EJ, Tuerk R et al. Dual mechanisms regulating AMPK kinase action in the ischemic heart. Circ Res 2005; 96(3):337-345.
10. Oliveira SM, Ehtisham J, Redwood CS, Ostman-Smith I, Blair EM, Watkins H. Mutation analysis of AMP-activated protein kinase subunits in inherited cardiomyopathics: implications for kinase function and disease pathogenesis. J Mol Cell Cardiol 2003; 35(10):1251-1255.
11. Ahmad F, Arad M, Musi N, He H, Wolf C, Branco D et al. Increased alpha2 subunit-associated AMPK activity and PRKAG2 cardiomyopathy. Circulation 2005; 112(20):3140-3148.
12. Blair E, Redwood C, Ashrafian H, Oliveira M, Broxholme J, Kerr B et al. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 2001; 10(11):1215-1220.
13. Sidhu JS, Rajawat YS, Rami TG, Gollob MH, Wang Z, Yuan R et al. Transgenic mouse model of ventricular preexcitation and atrioventricular reentrant tachycardia induced by an AMP-activated protein kinase loss-of-function mutation responsible for Wolff-Parkinson-White syndrome. Circulation 2005; 111(1):21-29.
14. Lei B, Matsuo K, Labinskyy V, Sharma N, Chandler MP, Ahn A et al. Exogenous nitric oxide reduces glucose transporters translocation and lactate production in ischemic myocardium in vivo. Proc Natl Acad Sci U S A 2005; 102(19):6966-6971.
15. Tokarska-Schlattner M, Zaugg M, da Silva R, Lucchinetti E, Schaub MC, Wallimann T et al. Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply. Am J Physiol Heart Cite Physiol 2005; 289(1):H37-H47.
16. Russell RR, III, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 2004; 114(4):495-503.
17. Murphy RT, Mogensen J, McGarry K, Bahl A, Evans A, Osman E et al. Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history. J Am Coll Cardiol 2005; 45(6):922-930.
18. Musi N, Hirshman MF, Arad M, Xing Y, Fujii N, Pomerleau J et al. Functional role of AMP-activated protein kinase in the heart during exercise. FEBS Lett 2005; 579(10):2045-2050.
19. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005; 1(1): 15-25.
20. Liao Y, Takashima S, Maeda N, Ouchi N, Komamura K, Shimomura I et al. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism Cardiovasc Res 2005; 67(4):705-713.
21. Richey PA, Brown SP. Pathological versus physiological left ventricular hypertrophy: a review. J Sports Sci 1998; 16(2):129-141.
22. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 2000; 102(4):470-479.
23. Chien KR, Zhu H, Knowlton KU, Miller-Hance W, van Bilsen M, O'Brien TX et al. Transcriptional regulation during cardiac growth and development Annu Rev Physiol 1993; 55:77-95.
24. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003; 65:45-79.
25. Tian R, Musi N, D'Agostino J, Hirshman MF, Goodyear LJ. Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 2001; 104(14):1664-1669.
26. Gollob MH, Green MS, Tang AS, Gollob T, Karibe A, Ali Hassan AS et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 2001; 344(24):1823-1831.
27. Arad M, Benson DW, Perez-Atayde AR, McKenna WJ, Sparks EA, Kantor RJ et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest 2002; 109(3):357-362.
28. Chan AY, Soltys CL, Young ME, Proud CG, Dyck JR. Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J Biol Chem 2004; 279(31):32771-32779.
29. Browne GJ, Finn SG, Proud CG. Stimulation of the AMP-activated protein kinase leads to activation of eukaryotic elongation factor 2 kinase and to its phosphorylation at a novel site, serine 398. J Biol Chem 2004; 279(13):12220-12231.
30. Browne GJ, Proud CG. A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin. Mol Cell Biol 2004; 24(7):2986-2997.
31. Cheng SW, Fryer LG, Carling D, Shepherd PR. Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status. J Biol Chem 2004; 279(16):15719-15722.
32. Chan AY, Dyck JR. Activation of AMP-activated protein kinase (AMPK) inhibits protein synthesis: a potential strategy to prevent the development of cardiac hypertrophy. Can J Physiol Pharmacol 2005; 83(1):24-28.
33. Browne GJ, Proud CG. Regulation of peptide-chain elongation in mammalian cells. Eur J Biochem 2002; 269(22):5360-5368.
34. Ryazanov AG, Shestakova EA, Natapov PG. Phosphorylation of elongation factor 2 by EF-2 kinase affects rate of translation. Nature 1988; 334(6178):170-173.
35. Ryazanov AG, Davydova EK. Mechanism of elongation factor 2 (EF-2) inactivation upon phosphorylation. Phosphorylated EF-2 is unable to catalyze translocation. FEBS Lett 1989; 251(1-2):187-190.
36. 2+/ calmodulin-dependent system of protein phosphorylation. Biochimie 1988; 70(5):619-626.
37. Carlberg U, Nilsson A, Nygard O. Functional properties of phosphorylated elongation factor 2. Eur J Biochem 1990; 191(3):639-645.
38. 2+ /calmodulin-independent activity. Biochem. J 2001; 353(Pt 3):621-626.
39. Knebel A, Morrice N, Cohen P. A novel method to identify protein kinase substrates: eEF2 kinase is phosphorylated and inhibited by SAPK4/ p38delta. EMBO J 2001; 20(16):4360-4369.
40. Knebel A, Haydon CE, Morrice N, Cohen P. Stress-induced regulation of eukaryotic elongation factor 2 kinase by SB 203580-sensitive and -insensitive pathways. Biochem J 2002; 367(Pt 2):525-532.
41. Wang X, Li W, William M, Terada N, Alessi DR, Proud CG. Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J 2001; 20(16):4370-4379.
42. Horman S, Beauloye C, Vertommen D, Vanoverschelde JL, Hue L, Rider MH. Myocardial ischemia and increased heart work modulate the phosphorylation state of eukaryotic elongation factor-2. J Biol Chem 2003; 278(43):41970-41976.
43. Horman S, Browne G, Krause U, Patel J, Vertommen D, Bertrand L et al. Activation of AMP-activated protein kinasia leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol 2002; 12(16):1419-1423.
44. Terai K, Hiramoto Y, Masaki M, Sugiyama S, Kuroda T, Hori M et al. AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress. Mol Cell Biol 2005; 25(21):9554-9575.
45. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Crones Dev 2001; 15(7):807-826.
46. Martin DE, Hall MN. The expanding TOR signaling network. Curr Opin Cell Biol 2005; 17(2):158-166.
47. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18(16):1926-1945.
48. Bolster DR, Crozier SJ, Kimball SR, Jefferson LS. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem 2062; 277(27):23977-23980.
49. Cheng SW, Fryer LG, Carling D, Shepherd PR. Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status. J Biol Chem 2004; 279(16):15719-15722.
50. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003; 115(5):577-590.
51. Krymskaya VP. Tumour suppressors hamartin and tuberin: intracellular signalling. Cell Signal 2003; 15(8):729-739.
52. Garami A. Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 2003; 11(6):1457-1466.
53. Kwiatkowski DJ. Tuberous sclerosis: from tubers to mTOR. Ann Hum Genet 2003; 67(Pt 1):87-96.
54. Fryer LG, Carling D. AMP-activated protein kinase and the metabolic syndrome. Biochem Soc Trans 2005; 33(Pt 2):362-366.
55. Pold R, Jensen LS, Jessen N, Buhl ES, Schmitz O, Flyvbjerg A et al. Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes 2005; 54(4):928-934.
56. Richards SK, Parton LE, Leclerc I, Rutter GA, Smith RM. Over-expression of AMP-activated protein kinase impairs pancreatic {beta}-cell function in vivo. J Endocrinol 2005; 187(2):225-235.
57. Carroll R, Carley AN, Dyck JR, Severson DL. Metabolic effects of insulin on cardiomyocytes from control and diabetic db/db mouse hearts. Am J Physiol Endocrinol Metab 2005; 288(5):E900-E906.
58. Li J, Miller EJ, Ninomiya-Tsuji J, Russell RR, III, Young LH. AMP-activated protein kinase activates p38 mitogen-activated protein kinase by increasing recruitment of p38 MAPK to TAB1 in the ischemic heart. Circ Res 2005; 97(9):872-879.
59. An D, Kewalramani G, Qi D, Pulinilkunnil T, Ghosh S, Abrehani A et al. beta-Agonist stimulation produces changes in cardiac AMPK and coronary lumen LPL only during increased workload. Am J Physiol Endocrinol Metab 2005; 288(6):E1120-E1127.
60. Du JH, Xu N, Song Y, Xu M, Lu ZZ, Han C et al. AICAR stimulates IL-6 production via p38 MAPK in cardiac fibroblasts in adult mice: a possible role for AMPK. Biochem Biophys Res Commum 2005; 337(4):1139-1144.
61. Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, Pimentel DR et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 2004; 10(12):1384-1389.
62. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K et al. Adiponectin protects against myocardial ischemia-reperfusion injury through. Nat Med 2005; 11:1096-1103.